Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

APO-ELTROMBOPAG 50 MG

ELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG · DIN 02506769 · APOTEX INC

Health Canada status: MARKETED

What is APO-ELTROMBOPAG?

APO-ELTROMBOPAG 50 MG contains ELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02506769, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is APO-ELTROMBOPAG used for?

APO-ELTROMBOPAG tablets are indicated for the treatment of chronic immune thrombocytopenia (ITP) to increase platelet counts in adult and pediatric patients one year and older who have had an insufficient response to corticosteroids or immunoglobulins. APO-ELTROMBOPAG is indicated to increase platelet counts in thrombocytopenic patients with chronic hepatitis C virus (HCV) infection to allow the initiation and maintenance of interferon-based therapy. APO-ELTROMBOPAG is indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02506769
Brand nameAPO-ELTROMBOPAG
Generic / active ingredientELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG
ManufacturerAPOTEX INC
Strength50 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeB02BX05 ELTROMBOPAG
AHFS class20:16.00
BiosimilarNo
Health Canada statusMARKETED
Status date23-May-2023
Original market date2023-05-23 00:00:00

How is it stored and handled?

null

How is it supplied?

null

What can be used instead?

Other Canadian products sharing ATC code B02BX05 ELTROMBOPAG. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-ELTROMBOPAG25 MGTABLETAPOTEX INCMARKETEDDIN 02506742
REVOLADE25 MGTABLETNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02361825
REVOLADE50 MGTABLETNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02361833
REVOLADE12.5 MGTABLETNOVARTIS PHARMACEUTICALS CANADA INCCANCELLED PRE MARKETDIN 02461382
REVOLADE75 MGTABLETNOVARTIS PHARMACEUTICALS CANADA INCCANCELLED PRE MARKETDIN 02423049
TEVA-ELTROMBOPAG25 MGTABLETTEVA CANADA LIMITEDAPPROVEDDIN 02551721
TEVA-ELTROMBOPAG50 MGTABLETTEVA CANADA LIMITEDAPPROVEDDIN 02551748

Who else supplies ELTROMBOPAG worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ELTROMBOPAG appears in 217 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for APO-ELTROMBOPAG

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for APO-ELTROMBOPAG

Health Canada Drug Product Database (DPD), DIN 02506769. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.